Functionalised cyclopentadienyl zirconium compounds as potential anticancer drugs.
New neutral and ionic functionalised zirconocene dichloride compounds have been isolated and characterised. The ionic zirconocene exhibits excellent cytotoxicity against a range of human tumour cell lines, which represents the first active anticancer zirconocene dichloride compound.
Allen
Olivia R
OR
Department of Chemistry, University of Leeds, Leeds, UK LS2 9JT.
Knox
Richard J
RJ
McGowan
Patrick C
PC
D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002712:Chlorides / Q000737:chemistry; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D006801:Humans; D020128:Inhibitory Concentration 50; D007477:Ions; D009682:Magnetic Resonance Spectroscopy; D008956:Models, Chemical; D009942:Organometallic Compounds / Q000494:pharmacology; D013053:Spectrophotometry / Q000379:methods; D015040:Zirconium / Q000737:chemistry* / Q000494:pharmacology
D000970:Antineoplastic Agents; D002712:Chlorides; D007477:Ions; D009942:Organometallic Compounds; C023398:Zirconocene dichloride; D015040:Zirconium